GlassScriptPhysician profile
Khiem Nguyen
NPI 1316922511
$11,577.37
in general payments reported to CMS, 2019-2025
27 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,796 · 2020: $467 · 2021: $606 · 2022: $718 · 2023: $7,580 · 2024: $234 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,700 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Food and Beverage: $949 · Travel and Lodging: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,700.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Food and Beverage | $949.05 |
| Travel and Lodging | $841.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $7,701.77 | 2020-2023 | Gimoti |
| Olympus Corporation of The Americas | $1,007.04 | 2019 | |
| Abbvie INC. | $398.12 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $378.29 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $357.15 | 2019-2025 | Entyvio, Eohilia |
| Ironwood Pharmaceuticals, INC | $312.67 | 2020-2025 | |
| Janssen Biotech, INC. | $306.08 | 2019-2024 | Tremfya, Stelara, Simponi Aria |
| Braintree Laboratories, INC. | $232.80 | 2020-2022 | |
| Pfizer INC. | $209.55 | 2019-2024 | |
| Gilead Sciences, INC. | $209.54 | 2019-2022 | |
| Olympus America INC. | $85.43 | 2020-2023 | Single Use Aspiration Needle Na-U200h |
| Boston Scientific Corporation | $56.08 | 2020-2025 | General - Biliary Devices, Spyglass |
| Allergan, INC. | $38.90 | 2019 | |
| Conmed Corporation | $37.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.82 | 2024 | Dupixent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $23.10 | 2025 | Zenpep |
| Digestive Care, INC. | $21.46 | 2025 | Pertzye |
| Horizon Therapeutics Plc | $20.89 | 2022 | |
| Lilly USA, LLC | $20.58 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $19.84 | 2024 | Dificid |
| Redhill Biopharma INC. | $19.81 | 2021 | |
| Shield Therapeutics INC | $18.58 | 2025 | |
| Ardelyx, INC. | $17.78 | 2024 | Ibsrela |
| Celgene Corporation | $17.51 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.04 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $15.21 | 2019 | |
| Qol Medical, LLC | $9.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khiem Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.